Mindset Pharma Commences In Vivo Program for Its Proprietary Next Generation Psychedelic Drug Candidates and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - October 20, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company at the forefront of the evolving psychedelics space, today announced that it has begun confirmatory in-vivo studies with InterVivo Solutions Inc. ("InterVivo Solutions") to further profile the efficacy, safety and pharmacological properties of Mindset's broad portfolio of patent-pending psychedelic drug candidates. Mindset was established to...
2020-10-20 7:00 AM EDT
Mindset Pharma Inc. and North Sur Complete Combination; North Sur Changes Name to Mindset Pharma Inc.
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2020) - Mindset Pharma Inc. (formerly, North Sur Resources Inc.) (the "Company") is pleased to announce that it has completed its previously announced business combination with Mindset Pharma Inc. ("Mindset"). The business combination was carried out pursuant to the terms of a share exchange agreement (the "Share Exchange Agreement") dated July 31, 2020, pursuant to which the Company acquired all of the issued and outstanding common...
2020-09-15 7:00 AM EDT
Mindset Pharma Synthesizes Second Generation Medicinal Psychedelic Compounds
Toronto, Ontario--(Newsfile Corp. - May 6, 2020) - Mindset Pharma ("Mindset"), a leading drug discovery business focused on developing next-generation psychedelic medicines, announced today that it has successfully synthesized approximately one-quarter of the target compounds identified in its previously filed patent applications, with another quarter of the compounds in late stages of synthesis. Within two months, Mindset expects to complete the synthesis of its additional target compounds...
2020-05-06 9:00 AM EDT